Diagnostic Influenza RT-PCR Array
Small Business Information
AKONNI BIOSYSTEMS, INC.
400 Sagner Avenue, Suite 300, Frederick, MD, -
AbstractDESCRIPTION (provided by applicant): Influenza viruses are highly contagious negative-sense RNA viruses cause approximately 114,000 hospitalizations and 20,000 deaths annually. Several drugs are approved by the US Food and Drug Administration (FDA) for tre ating influenza infections, but successful treatment depends on knowing the specific antigenic subtype and administering these drugs within the first 48 h of illness. Recent outbreaks of avian influenza H5N1 in East Asia have fueled concern over another pa ndemic and emphasize the need for comprehensive strain sub-typing in surveillance and diagnostic applications. The objective of this Phase 2 Project is therefore to develop and field test a sample-to-answer RT-PCR array kit for influenza detection and anti genic sub-typing in diagnostic and surveillance settings, with an emphasis on simple, low-cost microarray technology that can be deployed and used in peripheral hospital labs. The performance goal is a sample-to answer result in 2 hours or less at an input target concentration of 102 viral particles per mL nasopharyngeal swab. Early adopters at Wadsworth Center, Columbia University, Little Company of Mary Hospital and the CDC will assist in the pre-clinical verification of the technology on amended and blin d clinical samples. PUBLIC HEALTH RELEVANCE: The influenza RT-PCR array will be the first-of-its-kind combination of PCR and microarray technology in a simple, inexpensive test kit for disease surveillance and diagnosis. The underlying platform developed h erein will likewise find broad application in many areas of infectious disease diagnostics.
* information listed above is at the time of submission.